MEDNAX Inc (MD) Shares Sold by Quantamental Technologies LLC

Share on StockTwits

Quantamental Technologies LLC reduced its stake in MEDNAX Inc (NYSE:MD) by 78.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,202 shares of the company’s stock after selling 4,499 shares during the quarter. Quantamental Technologies LLC’s holdings in MEDNAX were worth $33,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its position in shares of MEDNAX by 538.6% during the 1st quarter. Quadrant Capital Group LLC now owns 1,009 shares of the company’s stock worth $26,000 after acquiring an additional 851 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of MEDNAX by 3,200.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,223,145 shares of the company’s stock worth $37,000 after acquiring an additional 1,186,080 shares in the last quarter. Tompkins Financial Corp boosted its position in shares of MEDNAX by 352.8% during the 1st quarter. Tompkins Financial Corp now owns 806 shares of the company’s stock worth $38,000 after acquiring an additional 628 shares in the last quarter. Investors Research Corp acquired a new stake in shares of MEDNAX during the 1st quarter worth approximately $41,000. Finally, Bremer Trust National Association acquired a new stake in MEDNAX in the fourth quarter valued at approximately $44,000. 93.46% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Md Pascal J. Goldschmidt sold 3,300 shares of MEDNAX stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $30.40, for a total transaction of $100,320.00. Following the completion of the transaction, the director now owns 20,821 shares of the company’s stock, valued at $632,958.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Dominic J. Andreano sold 1,289 shares of MEDNAX stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $36.22, for a total transaction of $46,687.58. Following the transaction, the senior vice president now directly owns 69,069 shares of the company’s stock, valued at approximately $2,501,679.18. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,779 shares of company stock worth $897,454. 3.40% of the stock is owned by company insiders.

A number of analysts have weighed in on the stock. Credit Suisse Group cut their target price on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 13th. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Mizuho set a $36.00 target price on shares of MEDNAX and gave the company a “hold” rating in a research report on Friday, February 8th. Citigroup set a $36.00 target price on shares of MEDNAX and gave the company a “buy” rating in a research report on Friday, May 3rd. Finally, Jefferies Financial Group cut their target price on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating on the stock in a research report on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $40.55.

Shares of NYSE:MD opened at $28.51 on Thursday. The firm has a market cap of $2.47 billion, a PE ratio of 8.12, a price-to-earnings-growth ratio of 1.10 and a beta of 0.59. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.79. MEDNAX Inc has a 52 week low of $25.47 and a 52 week high of $48.77.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.05). The business had revenue of $851.20 million for the quarter, compared to analyst estimates of $906.35 million. MEDNAX had a positive return on equity of 9.82% and a negative net margin of 1.05%. MEDNAX’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the firm posted $0.89 EPS. Equities analysts anticipate that MEDNAX Inc will post 3.15 earnings per share for the current year.

WARNING: “MEDNAX Inc (MD) Shares Sold by Quantamental Technologies LLC” was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://weekherald.com/2019/05/16/mednax-inc-md-shares-sold-by-quantamental-technologies-llc.html.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Recommended Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.